Free Mesothelioma Information Packet

Papillary Mesothelioma

Papillary mesothelioma is better and more commonly referred to among the medical establishment as well-differentiated papillary mesothelioma, or WDPM. Papillary mesothelioma, unlike other mesotheliomas, is generally considered to be of low malignant potential. Papillary mesothelioma is also likely to stay localized and not spread to other areas of the body outside of its origin.

Treatment for papillary mesothelioma is not standardized, as this particular typed of mesothelioma is extraordinarily rare. Surgery is typically recognized as the preferred treatment and is often available to patients diagnosed with papillary mesothelioma. Other treatments include several types of chemotherapy, including those used for traditional mesothelioma tumors.

This particular mesothelioma is not associated with any particular symptoms. The disease is classified as clinically indolent, meaning there is relatively no pain or discomfort associated with the mesothelioma and the tumor is relatively inactive. Those diagnosed with papillary mesothelioma are typically expected to make a complete recovery and prognosis is positive across the board. The most common papillary mesothelioma tumors form within the peritoneum (membrane which surrounds the abdominal cavity) in women of reproductive age. Other cases have been documented as originating in the lining of the heart and lungs.

Unlike malignant mesotheliomas, which are typically associated with asbestos exposure, there is no conclusive evidence linking papillary mesothelioma to asbestos exposure and those diagnosed with papillary mesothelioma will often have no asbestos history of significance.

References:
  • Butnor, K., Sporn, T., Hammar, S. et al. Well-Differentiated Papillary Mesothelioma. (2001). The American Journal of Surgical Pathology: 1304-1309.
  • · · Spano, J., Soria, J., Sabourin J. Well-Differentiated Papillary Mesothelioma (WDPM): Successful therapy by local surgery alone or combined with intraoperative intraperitoneal heated chemotherapy (IPHC) perfusion using cisplatin. (2003). Proceeding of the American Society for Clinical Oncology; 22.

Last modified: February 15, 2010.